Hepatitis C

Seminars in Liver Disease

Volumn 29, Issue 1, 2009, Pages 53-65

  Burra, Patrizia ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiviral therapy; Hcv recurrence; Liver fibrosis progression

Indexed keywords

ALEMTUZUMAB; ALPHA2B INTERFERON; AZATHIOPRINE; CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISOLONE; RAPAMYCIN; RIBAVIRIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE DISEASE; BILE DUCT OBSTRUCTION; BLOOD VESSEL INJURY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC GRAFT REJECTION; CYTOPENIA; DISEASE COURSE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MENTAL DISEASE; MONOTHERAPY; ORGAN DONOR; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; RETRANSPLANTATION; SEPSIS; THYROID DISEASE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 63049089022     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1192055     Document Type: Article

References (95)

1. Organ Procurement and Transplantation Network. Current U.S. waiting list candidates for liver transplant. Available at: http://ww.optn.org/latestData/ rtpData.asp. Accessed August23, 2008
2. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003;9:1231-1243
3. Forman LM, Lewis JD, Berlin J A, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896
4. Féray C, Caccamo L, Alexander GJ, et al. European Collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625
5. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003;9:905-915
6. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355
7. Forns X, Garćfa-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-396
8. Everson GT, Trotter j, Forman L, et al Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-262
9. Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006;13:762-769
10. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial J Hepatol 2007;47:484-491
11. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alpha-2b and ribavirin in patients with hepatitis C virus and
12. decompensated cirrhosis; a controlled study. J Hepatol 2007;46:206-212
13. Bruno S, Stroffolini T, Colombo M, et al, Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-587
14. Mutimer DJ, Gunson B, Chen J. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006;81:7-14
15. Rayhili SC, Wu YM, Katz DA. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007;84:331-339
16. Grazi GL, Cescon M, Ravaioli M, Corti B, Pinna AD. Successful liver transplantation from a 95-year-old donor to a patient with MELD score 36 and delayed graft arterialization. Am J Transplant 2008;8:725-726
17. Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006;12:1496-1503
18. Segev DL, Kucirka LM, Nguyen GC, et al. Effect modification in liver allografts with prolonged cold ischemic time. Am J Transplant 2008;8:658-666
19. Hong JC, Busuttil RW. Cold ischemia time and liver graft survival. Am J Transplant 2008;8:481-482
20. Burra P, Loreno M, Russo FP, et al. Donor livers with steatosis are safe to use in HCV-positive recipients. Liver Transpl 2009. In press
21. Botha JF, Thompson E, Gilroy R, et al, Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007; 27:758-763
22. Bricefio J, Ciria R, Pleguezuelo M, et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007;39:2297-2299
23. Muiesan P, Girlanda R, Jassem W, et al. Single-center experience with liver transplantation from controlled non-heartbeating donors; a viable source of grafts, Ann Surg 2005;242:732-738
24. Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13:122-129
25. Humar A, Horn K, Kalis A, et al. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant 2005;5:399-405
26. Lawal A, Ghobria! R, Te H, et al. Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation. Transplant Proc 2007;39:3261-3265
27. Saraf N, Fiel MI, Deboccardo G, Emre S, Schiano TD. Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation. Liver Transpl 2007; 13:913-917
28. Bilbao I, Dopazo C, Lazaro JL, et al. Our experience in liver transplantation in patients over 65 yr of age. Clin Transplant 2008;22:82-88
29. Cameron AM, Ghobrial RM, Hiatt JR, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006;244:563-571
30. Belli LS, Burroughs AK, Burra P, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007;13:733-740
31. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE, Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008;48:80-87
32. Seo S, Maganti K, Khehra M, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007;13:844-847
33. Petta S, Cammā C, Marco VD, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection, Am J Gastroenterol 2008;103:1136-1144
34. Mallat A, Hezode C, Lotersztajn S. Environmental factors as disease accelerators during chronic hepatitis C. J Hepatol 2008;48:657-665
35. Burra P, Mioni D, Cecchetto A, et al. Histological features after liver transplantation in alcoholic cirrhotics, j Hepatol 2001;34:716-722
36. Belli LS, Zavaglia C, Alberti AB, et al. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation. Hepatology 2000;31: 1345-1350
37. Belli LS, Burra P, Poli F, et al, HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006;130:695-702
38. Fishman J A, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-1751
39. Lucas M, Vargas-Cuero AL, Lauer GM, et al, Pervasive influence of hepatitis c virus on the phenotype of antiviral CD8+ T cells. J Immunol 2004;172:1744-1753
40. Nebbia G, Mattes FM, Cholongitas E, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007;13:130-135
41. Teixeira R, Pastacaldi S, Davies S, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation, Transplantation 2000;70;1454-1458
42. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-369
43. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpes virus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2:461-466
44. Yilmaz N, Shiffman ML, Stravitz RT, et al A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007;13:975-983
45. Biggins SW, Terrauit NA, Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis 2005;9:505-523
46. Brown RS Jr. Hepatitis C and liver transplantation. Nature 2005;436:973-978
47. Shiffman ML, Vargus HE, Ever son GT. Controversies in the management of hepatitis C virus infection after liver transplantation, Liver Transpl 2003;9:1129-1144
48. Sebagh M, Rifai K, Feray C, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003;37: 1293-1301
49. Feray C, Fibrosis progression after liver transplantation in patients with recurrent hepatitis C, J Hepatol 2004;41:862-863
50. Guido M, Fagiuoli S, Tessari G, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002;50:697-700
51. Baiocchi L, Angelico M, Petrolati A, et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease. Am J Transplant 2008;8:673- 678
52. Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 2007;13; 219-226
53. Tretheway D, Jain A, LaPoint R, et al. Should trichrome stain be used on all post-liver transplant biopsies with hepatitis C virus infection to estimate the fibrosis score? Liver Transpl 2008;14:695-700
54. Yerian L. Identifying activated hepatic stellate cells in chronic and posttransplant recurrent hepatitis C. Liver Transpl 2008;14:756-758
55. Carotti S, Morini S, Corradini SG, et al. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl 2008;14:806-814
56. Rigamonti C, Donate MF, Fraquelli M, et al. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. Gut 2008; 57:821-827
57. Talwalkar JA, Yin M, Fidler JL, et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications, Hematology 2008;47:332-342
58. Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005;11:386-395
59. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34
60. Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92: 1453-1457
61. Berenguer M, Prieto M, Córdoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998;28:756-763
62. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820
63. Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007;84:829-835
64. Papatheodoridis GV, Davies S, Dhillon AP, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001;72; 412-418
65. Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008;14:512-525
66. Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007;47:793-798
67. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004;10:1258-1262
68. 67.Walter T, Dumortier J, Guillaud O, et al. Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transpl 2007;13:294-301
69. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78:966-971
70. Terrault NA. Treatment of recurrent hepatitis C in liver transplant recipients.Clin Gastroenterol Hepatol 2005 ;3: S125-S131
71. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746-1756
72. Angelico M, Petrolati A, Lionetti R, et al, A randomized study on peg-interferon alpha-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46:1009-1017
73. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alpha-2b and ribavirin combination. J Hepatol 2004;40:669-674
74. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with a combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004;77:190-194
75. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007;13;1100-1108
76. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alpha-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005;41:289-298
77. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005;5:118-124
78. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-650
79. Zimmermann T, Bocher WO, Biesterfeld S, et al. Efficacy of an escalating-dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation, Transpl Int 2007;20:583-590
80. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006;6:2348-2355
81. Heydtmann M, Freshwater D, Dudley T, et al. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006:6:825-833
82. Bcrardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56:237-242
83. Hanouneh 1A, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008;14:53-58
84. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and metaanalysis of prospective controlled studies. J Viral Hepat 2008; 10:699-709
85. Bizollon T, Pradat P, MabrutJY, et al. Histological benefit of retreatment by pegylated interferon alpha-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007;7:448-453
86. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl 2003;9:S95-S100
87. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004;78:1308-1311
88. 87.Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C, Liver Transpl Surg 1997;3:130-136
89. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830
90. Ghobrial RM, Farmer DC, Baquerizo A, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immuno-suppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-831
91. Ghobrial RM. Retransplantation for recurrent hepatitis C. Liver Transpl 2002;8:S38-S43
92. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999;29:365-370
93. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998;66: 1612-1616
94. Northup PG, Pruett TL, Kashmer DM, et al. Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index. Am J Transplant 2007;7:1984-1988
95. Ghabril M, Dickson R, Wiesner R, Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection. Am J Transplant 2008;8:404-411